Lecanemab May Avoid Aduhelm’s Fate With CMS

September 28, 2022

New data from Eisei suggests that its Alzheimer’s drug lecanemab may not share the same fate as aduhelm, which was pulled from the market after the Centers for Medicare and Medicaid Services (CMS) agreed to only reimburse the drug for patients in randomized clinical trials. The results show that the drug was able to slow cognitive decline by 27% over 18 months, which may meet the agency’s requirements. However, Eisei is being cautious with its pricing.

According to Zachary Brennan, “Eisai said in June that its annual value-based price of lecanemab “was estimated at $9,249 to $35,605 (Societal perspective: $10,400 to $38,053)” based on an early economic assessment. And surely Eisai learned its lesson from Biogen’s fiasco with Aduhelm’s price slashed in half to $28,200 less than six months after launch. And where many thought Aduhelm could be the straw that breaks Medicare’s back, with tens of billions in new sales following approval, lecanemab could create the same sort of issues for government spending.”

To read more, click here.

(Source: Endpoints News, September 28th, 2022)

Share This Story!